First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. - Wikidata - wikimedia - TriplyDB

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.

http://www.wikidata.org/entity/Q37433474

about

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study.Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.3-(Benzo[d][1,3]dioxol-5-ylamino)-N-(4-fluorophenyl)thiophene-2-carboxamide overcomes cancer chemoresistance via inhibition of angiogenesis and P-glycoprotein efflux pump activity.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Contrast agents in dynamic contrast-enhanced magnetic resonance imaging.New targets and therapies for gastrointestinal stromal tumors.Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors

P2860

Q26740567-15FA7155-092D-4661-8D60-EC183CF7232E Q34229404-87D89F10-DBE1-44FE-B258-DA4A25DACBB4 Q35511058-DAD9A8BB-8477-4B2A-BE3C-3D8C536E47BB Q38901475-7ADACD5E-1C88-4651-951D-B5D7646F911B Q38925022-216E257E-0F4F-421B-BA19-9FA586245D44 Q39246340-F1B6F759-6B7F-46DE-846D-A4F3427B1D68 Q47432725-6D77A203-354F-4D04-BEB4-278CC4051DEE Q58759036-073E61A6-EF04-4187-928C-413631245E54

P2860

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.

http://www.wikidata.org/entity/Q37433474

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

First-in-human phase I trial o ...... al proof-of-mechanism studies.

@en

First-in-human phase I trial o ...... al proof-of-mechanism studies.

@nl

type

label

First-in-human phase I trial o ...... al proof-of-mechanism studies.

@en

First-in-human phase I trial o ...... al proof-of-mechanism studies.

@nl

prefLabel

First-in-human phase I trial o ...... al proof-of-mechanism studies.

@en

First-in-human phase I trial o ...... al proof-of-mechanism studies.

@nl

P1433

Q37433474-43A0B9B3-9B11-4B38-8A29-50A479D3E02B

P1476

Q37433474-2B006564-9A8A-4FEC-8877-06A1F990B8AE

P2093

Q37433474-02A23D6F-540A-4C70-8F92-C750401D1A93

Q37433474-1D032AC6-CC0B-4832-8C7D-437E37F5D59F

Q37433474-35B171B2-2962-4879-95A6-40FFF69E12FA

Q37433474-3C5997DC-19D7-443B-8911-AE6FD173335C

Q37433474-50AACE88-D27B-4862-8E80-DF44090CB30A

Q37433474-57A86B93-6452-496D-8DEC-2414597C9054

Q37433474-64BB29A4-EE3D-4FB9-9F92-6F831F09608A

Q37433474-79201187-4D70-4160-A9E0-8A281C856CA3

Q37433474-82807C38-4A35-421A-AB03-B11CBB93C7E4

Q37433474-8794B1E3-7139-4F33-8673-ACCB657800A1

P2860

Q37433474-0831A40C-BC60-44BB-AEF3-CF4ED71150BC

Q37433474-198032E8-3C0E-4BB3-A5E9-91ED7A056E87

Q37433474-26F870A5-0F57-4203-B50B-A5B41FDCE57C

Q37433474-27620F19-5F2A-4C7D-8A65-4E6EEB32FE6A

Q37433474-360034D7-EFB1-4CEF-AE4D-B69B21BC2777

Q37433474-36492D3B-8943-4BF1-AB73-453488FAA87B

Q37433474-367F7A38-F4F8-402F-B6DE-701D923DF9E3

Q37433474-370AD3A1-603A-4835-AABF-7E8F5A26A694

Q37433474-4594952C-948A-4241-8798-299E2C555886

Q37433474-4B1D68E3-57D5-499C-884B-DE35769A4B97

P304

Q37433474-3319937F-CE2B-428F-A109-AC21376A830B

P31

Q37433474-590194A9-0F70-472C-9603-31568FED8F33

P356

Q37433474-F71C80F2-3274-46AA-A048-C75EA176AE86

P407

Q37433474-1BF05E81-163C-4FBD-90E4-6FA2B7134215

P433

Q37433474-96B3FB29-27B2-487C-9334-97FE861F5F71

P478

Q37433474-C9C6737A-8705-492B-A9A1-BEB9B33A96E6

P50

Q37433474-8586102F-38A0-42B4-BC4D-F89D469FF83B

P577

Q37433474-3292CC0E-8B2A-486D-B6D3-08CCDF66B76E

P698

Q37433474-912B7B8F-C12E-4699-BC9F-56D7C8F00B6B

P921

Q37433474-DC19E1E9-E1D0-4938-A548-5592B5FFD5EE

P932

Q37433474-ADC0816C-E994-4562-8026-6E1979C885C7

P356

1078-0432.CCR-12-2258

P1433

Clinical Cancer Research

P1476

First-in-human phase I trial o ...... nal proof-of-mechanism studies

@en

P2093

Andrew Stephens

http://www.w3.org/2001/XMLSchema#string

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

George Demetri

http://www.w3.org/2001/XMLSchema#string

Hendrik-Tobias Arkenau

http://www.w3.org/2001/XMLSchema#string

James Spicer

http://www.w3.org/2001/XMLSchema#string

Jennifer L Spratlin

http://www.w3.org/2001/XMLSchema#string

Jon Chick

http://www.w3.org/2001/XMLSchema#string

Katie Brock

http://www.w3.org/2001/XMLSchema#string

Michelle Scurr

http://www.w3.org/2001/XMLSchema#string

Nandita M Desouza

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

Molecular mechanisms and clinical applications of angiogenesis

Targeting cancer with small molecule kinase inhibitors

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data.

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.

P304

909-919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-2258

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23403628

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3880798

http://www.w3.org/2001/XMLSchema#string